Innate Pharma (IPHYF) Other Non-Current Assets (2017 - 2025)

Innate Pharma's Other Non-Current Assets history spans 9 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 79.41% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $1.1 million, up 79.41%, while the annual FY2025 figure was $1.1 million, 77.13% up from the prior year.
  • Other Non-Current Assets reached $1.1 million in Q4 2025 per IPHYF's latest filing, up from $614442.4 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $1.1 million in Q4 2025 to a low of $93606.8 in Q4 2023.
  • Average Other Non-Current Assets over 5 years is $426344.6, with a median of $169307.7 recorded in 2021.
  • Peak YoY movement for Other Non-Current Assets: tumbled 38.42% in 2023, then surged 556.41% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $169307.7 in 2021, then dropped by 10.21% to $152016.9 in 2022, then tumbled by 38.42% to $93606.8 in 2023, then soared by 556.41% to $614442.4 in 2024, then surged by 79.41% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for IPHYF's Other Non-Current Assets are $1.1 million (Q4 2025), $614442.4 (Q4 2024), and $93606.8 (Q4 2023).